Form 4: AngioDynamics SVP/GM, Vascular Access, Chad Thomas Campbell, Reports Acquisition of Common Stock and Derivative Securities

Chad Thomas Campbell, SVP/GM, Vascular Access at AngioDynamics, reports the acquisition of common stock, performance rights, and non-qualified stock options.

Summary

• On July 17, 2024, Chad Thomas Campbell, SVP/GM, Vascular Access at AngioDynamics, acquired 12,350 shares of common stock representing restricted stock units.
• These restricted stock units vest in four equal annual installments starting July 17, 2025.
• Campbell also acquired 24,699 performance rights, each representing a contingent right to receive one share of common stock.
• The number of shares earned from performance rights will be based on total shareholder return relative to a peer group over a three-year period, with potential adjustments.
• Additionally, Campbell acquired 24,240 non-qualified stock options with an exercise price of $7.40, vesting in four equal annual installments beginning July 17, 2025, and expiring on July 17, 2034.
• Following these transactions, Campbell directly owns 65,366 shares of AngioDynamics common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard executive compensation practices, indicating confidence in the company's future, but doesn't contain any groundbreaking news.

Positives

• The acquisition of stock and derivative securities by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting schedules for the restricted stock units and stock options, as well as the performance-based vesting of the performance rights, suggest a long-term incentive structure for the executive.

Industry Context

This filing is a routine disclosure related to executive compensation and is common in publicly traded companies. It reflects standard practices for incentivizing and retaining key personnel.

Comparison to Industry Standards

• Executive compensation packages including stock options, restricted stock units, and performance rights are standard practice among publicly traded companies, including AngioDynamics' competitors such as Boston Scientific, Medtronic, and Stryker.
• The vesting schedules and performance metrics outlined in the filing are typical for aligning executive incentives with shareholder value creation, similar to compensation structures observed in comparable companies.

Stakeholder Impact

• Shareholders may view the executive's acquisition of company stock and derivative securities as a positive sign, aligning management's interests with their own.
• Employees may see this as a sign of stability and confidence in the company's leadership.

Key Dates